The number many people want first is a success rate. For stem cell therapy for ALS abroad, there is no reliable percentage showing that treatment stops, reverses, or cures amyotrophic lateral sclerosis (ALS). Stem cell treatment remains investigational. A clinic that promises a particular improvement needs to explain the evidence behind that claim.
Other numbers are useful, though. Your ALS function score, breathing measurements, the number of treatment steps, and the timing of follow-up can help you assess a proposal. They also show which parts of care must be planned before you leave home and which need to continue after you return.
There is no proven percentage of people whose ALS is halted or reversed by stem cell therapy.
The ALSFRS-R tracks daily function. It helps describe your starting point, not predict treatment benefit.
Intravenous, intrathecal, and intraspinal delivery involve different procedures and risks.
0 proven cures: what an overseas ALS offer can and cannot promise
ALS damages motor neurons, the nerve cells that control voluntary movement. It may begin in an arm or leg (limb-onset ALS) or with speech and swallowing changes (bulbar-onset ALS). ALS may be sporadic, with no known family history, or familial, associated with an inherited genetic change. Other clinically diagnosed presentations also occur. These descriptions matter to an overseas team because symptoms, breathing needs, and travel support differ from person to person.
Researchers are studying whether certain stem-cell-derived products can support nerve cells or alter inflammation. That is different from showing that transplanted cells replace damaged motor neurons or reliably slow ALS. Small studies and differing treatment methods do not provide a dependable success range or known duration of benefit. Ask whether an offered procedure is part of a registered clinical trial, what that trial measures, and what evidence supports its use outside a trial.
Established ALS care should continue whether you travel or not. This includes a multidisciplinary ALS team, treatments approved or appropriate for your situation, breathing and nutrition support, communication assistance, rehabilitation, and symptom care. An investigational procedure abroad should not require you to give up that care.
48 ALSFRS-R points and other numbers used to assess eligibility
The ALS Functional Rating Scale–Revised (ALSFRS-R) has 12 questions, each scored from 0 to 4, for a total of 0 to 48. It records abilities such as speech, swallowing, walking, and breathing. A single score does not tell a clinic whether stem cell treatment will work. Changes between assessments are more informative, and even those changes cannot prove that an investigational treatment caused an improvement.
An overseas clinic may also review forced vital capacity (FVC), a measure of how much air you can breathe out after a full breath, often reported as a percentage of the expected value. Breathing support use, swallowing safety, weight change, mobility, and the speed of symptom progression may affect eligibility and procedural risk. Different studies use different entry rules. There is no universal ALSFRS-R score, FVC percentage, age, or body mass index that makes someone a suitable candidate.
Older adults are not automatically excluded. Diabetes, smoking, a high body mass index, infection, or medicines that affect bleeding may alter the risk of a lumbar puncture, anesthesia, or an invasive procedure. Severe breathing weakness, difficulty managing secretions, or an inability to tolerate travel may make an offer unsuitable. The treating team should explain its criteria for your proposed route rather than applying a generic “healthy enough” label.
For a preliminary review, send your neurology diagnosis and examination notes, ALSFRS-R measurements with their assessment dates, breathing tests, genetic results if available, medication list, and reports of other significant conditions. Clinics may also request electromyography (EMG), a test of muscle electrical activity, and imaging used to rule out conditions that can resemble ALS. Remote review is not final clearance. The overseas clinician must reassess you in person before treatment.
Numbers and terms you may see in an ALS treatment plan
- ALSFRS-R
- A 0–48 score describing how ALS affects everyday activities. It is not a measure of whether stem cells are working.
- FVC and percentage predicted
- A breathing-test result compared with an expected value. Your team interprets it alongside symptoms and any breathing support you use.
- Autologous and allogeneic
- Cells originating from your own body or from a donor, respectively. The source affects collection, processing, testing, and regulatory questions.
- Intrathecal and intraspinal
- Delivery into the fluid around the spinal cord, or injection into spinal cord tissue. They are not interchangeable procedures.
3 delivery routes: compare the procedure, not just the word “stem cells”
Overseas proposals may differ in cell source, processing, dose, delivery route, and whether treatment is repeated. A product described only as “stem cells” is not specific enough to assess. Ask for the exact cell type, whether it comes from you or a donor, the processing laboratory, product name or manufacturer where applicable, batch identification, release testing, and the regulatory authorization for its proposed use. Brand names and product descriptions can differ between programs, so obtain these details in writing.
The route changes what happens to your body. This comparison is more useful than comparing headline prices alone.
| Route | What happens | Questions for travel planning |
|---|---|---|
| Intravenous | A product enters a vein through an infusion. | What reactions are monitored, and what evidence supports this product and route in ALS? |
| Intrathecal | A lumbar puncture delivers a product into spinal fluid. | How are headache, infection, bleeding risk, and new neurological symptoms managed? |
| Intraspinal | A specialist places a product into spinal cord tissue through an invasive procedure. | Who performs it, what anesthesia and facility are required, and how is neurological injury assessed? |
Some research programs include cell collection and laboratory preparation before delivery. Others use a manufactured product. Confirm every proposed intervention separately. A plan for several infusions or injections is not evidence that more treatment is better.
4 steps an ALS cell-treatment proposal should make clear
- Confirm the diagnosis and baseline. The specialist reviews your records, examines you, and checks breathing and procedure-specific risks.
- Identify and verify the product. The team documents its source, processing, quality checks, authorization, and whether collection is needed.
- Deliver and monitor. The team uses the stated route and watches for immediate reactions or procedure-related problems.
- Measure and report follow-up. The clinic records adverse events and functional changes using a written schedule shared with your home ALS team.
No dependable complication percentage: plan for the risks you can identify
There is no single trustworthy complication-rate range for “stem cell therapy for ALS.” Products and procedures differ too much, and small studies may not detect uncommon harms. A clinic should provide adverse-event results for its specific product and route, state how many people were followed, and explain how it handles complications. A low reported rate without those details tells you little.
Possible problems include infusion reactions, infection, and harms related to an unproven cell product. Lumbar puncture can cause headache, bleeding, infection, or nerve-related symptoms. Intraspinal delivery adds risks associated with an invasive procedure and anesthesia, including neurological injury. ALS-related breathing or swallowing difficulties may increase the consequences of a complication.
Ask which clinician is responsible if you develop fever, a severe headache, new weakness, breathing trouble, or difficulty swallowing while near the treating team. Before traveling, also agree on what happens if symptoms start after you return. The overseas clinic may review records and advise remotely, but urgent assessment, breathing support, or treatment of an infection requires local care. A further invasive procedure might require another trip.
2 decisions before booking: investigate the offer and protect your home care
First, decide what you are comparing. A registered clinical trial has a defined research protocol, eligibility rules, oversight, and a plan for collecting outcomes and harms. A commercial offer is not equivalent simply because it uses similar language. Compare the clinical rationale, product and route, provider involvement, facility capabilities, monitoring, follow-up, and full financial commitment. The cheapest proposal is not necessarily the safest or the best fit.
Second, decide how treatment abroad would affect care at home. Your home ALS team may offer better continuity, easier rehabilitation and equipment adjustments, and faster help if symptoms change. Overseas care may offer access to a particular research program, but travel can be physically demanding and may separate treatment from the clinicians who know you best. Compare those trade-offs with a trial or other available care closer to home.
Treatment charges and total travel costs are different. The amount payable may depend on cell sourcing and processing, the delivery procedure, specialist and facility fees, testing, anesthesia, monitoring, and rehabilitation. Request a written quote showing whether consultations, diagnostics, medicines, hospital care, companion-related needs, accommodation, transfers, follow-up, and treatment of complications are included or excluded. A PlacidWay patient coordinator can help you obtain information about destinations, prices, travel arrangements, and the length of stay to discuss with the treating clinic.
When comparing programs across regions, focus on their ALS expertise, clinical-trial oversight, authorization for the exact product and use, laboratory controls, respiratory support, and access to emergency care. Ask for the treating neurologist’s and procedural specialist’s roles and credentials. If a spinal injection is proposed, verify the operator’s relevant training, the facility’s capabilities, and who would manage a neurological complication.
- Evidence: Is this a registered trial? What published evidence concerns this exact product, route, and ALS population?
- Clinical fit: Which of my ALS findings support eligibility, and what could lead to cancellation after an in-person examination?
- Safety: What adverse events have been recorded, who provides emergency care, and what happens if I need help at home?
- Practical terms: What is the written total quote, what is excluded, and what follow-up will you provide to my local doctor?
A credible proposal names the treating provider, specifies the product and procedure, gives a clinical reason for offering them to you, and explains uncertainty. It also sets out risks, the expected monitoring plan, inclusions and exclusions, and who handles follow-up. Vague product descriptions, unexplained success percentages, guaranteed recovery, or unclear pricing are reasons to pause.
4 care stages: which ALS milestones happen abroad and which happen at home
There is no universal recovery timetable for ALS cell procedures. An infusion, lumbar puncture, and invasive spinal delivery call for different observation and travel plans. Your breathing, swallowing, fatigue, mobility, and usual support needs also matter. The treating clinician should decide when travel is medically appropriate after examining you, not promise a departure date before assessment.
Before departure → prepare at home. Review the proposal with your ALS clinician. Arrange records, medicines, mobility and communication equipment, a companion if useful, and a plan for medical needs during travel. Do not change prescribed medicines without your treating doctor.
At the destination → complete final clearance. The team checks for changes since the remote review, confirms the procedure and consent, and assesses breathing, swallowing, infection, and anesthesia risks as relevant.
Immediately after treatment → remain near the treating team as advised. Monitoring focuses on reactions, procedure-site problems, headache, fever, breathing changes, or new neurological symptoms. The required observation depends on the procedure and your condition.
Back home → continue ALS care and longer-term measurement. Your local team manages routine ALS needs and urgent problems. The overseas provider should collect agreed follow-up results and review suspected treatment-related harms.
Before leaving the destination, obtain a discharge summary, procedural report, product identification and batch information, test results, prescriptions, emergency contact details, and written instructions for activity and warning signs. Give your home clinician the follow-up schedule and a named contact at the overseas clinic. If you have a new or severe symptom after returning, seek local medical care rather than waiting for a remote reply.
Long-term care is not a series of automatic “top-up” stem cell treatments. Your ALS team will keep reassessing breathing, nutrition, communication, mobility, and comfort as needs change. If an overseas provider recommends repeat treatment or a procedure to address a complication, ask for the clinical reason, new risks, supporting evidence, and who will coordinate care across borders.
1 next step: review an ALS stem cell proposal with a patient coordinator
If you are comparing investigational stem cell options abroad, a PlacidWay patient coordinator can help you request the product details, eligibility criteria, written quote, and follow-up plan you need to discuss with your ALS doctor.
Ask about ALS treatment options abroad
References
- National Institute of Neurological Disorders and Stroke — Amyotrophic Lateral Sclerosis (ALS)
- MedlinePlus — Amyotrophic Lateral Sclerosis
- U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products, Including Stem Cells and Exosomes
- International Society for Stem Cell Research — Stem Cell Research and Clinical Translation Resources
- ClinicalTrials.gov — Clinical Study Registry
This page is for general information and is not medical advice. Stem cell therapy for ALS is investigational, and you should consult a qualified doctor about your own diagnosis, treatment options, and travel plans.
Who stands behind this article
Health content should never be anonymous. Here are the people who wrote and checked it, with credentials you can verify independently.
Usama
Patient Care Writer
This author specializes in global healthcare trends and medical education. By focusing on evidence-based practices and a patient-first approach, they provide accessible resources to help readers understand their international treatment options with clarity.
Stem Cell Therapy, Longevity & Regenerative Medicine Specialist
Dr. Alejandro Fernando is a Mexico City-based physician and medical content reviewer focused on stem cell therapy, regenerative medicine, cellular therapy and longevity medicine. His reviewer profile lists medical and postgraduate training related to regenerative medicine, cellular therapy and stem cell biology.
How this article was checked
